TOG Review (RCOG Journal)
MRCOG Part 2
Urogynaecology and Pelvic Floor Problems
Management of refractory overactive bladder
Key Statistics
- >50% — OAB failing 1ST-line treatment
- 200/100 U — NICE onabotulinumtoxina dose
- ~10% / ~20% — Botox retention / UTI rates
Don't-miss facts
-
Refractory OAB has no agreed definition; 25–40% fail anticholinergics; MDT review mandatory before invasive therapy
-
NICE botulinum toxin A: 200 units standard, 100 units option (lower retention risk, reduced success); urodynamic- proven detrusor overactivity required by NICE (not by the drug licence for 100 units)
-
Injection technique: 10 U × 20 sites (200U) or 5 U × 20 sites (100U); effect lasts 3–6 months; only 10–15% need CIC
-
Avoid aminoglycosides post-botulinum toxin – may potentiate toxin/muscle relaxant effect
-
SNS: reoperation rate 33%; 9% need permanent removal; advanced evaluation → 70–90% progress to permanent implant vs 40–50% after peripheral nerve evaluation
-
PTNS: 12 weekly × 30 min sessions; benefit significant only from 13 weeks, not 7 weeks
-
Third-line surgery (diversion/clam cystoplasty) ~1% mortality; long-term catheter is a valid, often overlooked alternative
-
Mirabegron (beta-3 agonist): contraindicated in uncontrolled hypertension; adverse effects tachycardia, UTI
Treatment ladder at a glance
1st line: lifestyle, PFMT, bladder retraining 2nd line: antimuscarinics / mirabegron Refractory: botulinum toxin A, SNS, PTNS
3rd line: diversion, clam cystoplasty, long-term catheter
Abbreviation Key
- OAB — overactive bladder
- UTI — urinary tract infection
- ICS — International Continence Society
- CIC — clean intermittent catheterisation
- NICE — National Institute for Health and Care Excellence
- MDT — multidisciplinary team
- AUA — American Urological Association
- RCT — randomised controlled trial
- SNAP-25 — synaptosomal-associated protein 25
- BMI — body mass index
- SNS — sacral nerve stimulation
- CI — confidence interval
- PTNS — percutaneous (posterior) tibial nerve stimulation
Source: Wong J, Tincello DG. Management of refractory overactive bladder. The Obstetrician & Gynaecologist 2016;18:173–181. doi:10.1111/tog.12265
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).